文献速递脑血管病认知障碍与痴呆

多效药片、阿司匹林及其联合使用对认知与功能结局的影响:一项随机临床试验

Effects of a Polypill, Aspirin, and the Combination of Both on Cognitive and Functional Outcomes: A Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2023-01-01

TIPS-3 试验在 8 个国家纳入 5713 名有血管风险因素但无明确心血管疾病者,其中 2098 名 65 岁以上完成认知评估者进入分析。多效药片(降压药加他汀)单用或联合阿司匹林未显著减少认知下降,但多效药片组功能下降较安慰剂组减少(SAGEA 评分 0.06 vs 0.15,P=0.01),多效药片加阿司匹林组较双安慰剂组亦减少(0.01 vs 0.14,P=0.01)。

要点

  • 多效药片单用或联合阿司匹林未显著减少认知下降或痴呆。
  • 多效药片组功能下降较安慰剂组减少(SAGEA 评分 0.06 vs 0.15,P=0.01)。
  • 多效药片加阿司匹林组功能下降较双安慰剂组减少(SAGEA 评分 0.01 vs 0.14,P=0.01)。

核心结论

  • 在 65 岁以上有血管风险因素者中,多效药片联合或不联合阿司匹林未与认知结局降低相关,但与功能下降减少相关。

研究设计与样本

  • 国际 Polycap 研究 3(TIPS-3)为 2×2×2 析因随机临床试验。
  • 8 个国家医院和社区中心于 2012 年 7 月 30 日至 2020 年 9 月 30 日招募并随访参与者。
  • 共 5713 人随机分组,2098 名 65 岁以上中危心血管病风险者完成认知评估并纳入分析。

主要发现

  • 纳入分析的 2098 人中,平均(SD)年龄 70.1(4.5)岁,女性 1266 人(60%)。
  • 1796 人(86%)有高血压,680 人(32%)有空腹血糖受损。
  • 基线平均(SD)收缩压 146.1(17.7)mm Hg,LDL-C 124.3(40.7)mg/dL;多效药片组分别降低 5.7 mm Hg 和 24 mg/dL。
  • 5 年随访期间,多效药片组与安慰剂组实质性认知下降人数(356 vs 328)和痴呆人数(2 vs 4)无显著差异。
  • 功能下降:多效药片组较安慰剂组 SAGEA 评分 0.06(0.03)vs 0.15(0.03),P=0.01;多效药片加阿司匹林组较双安慰剂组 0.01(0.04)vs 0.14(0.04),P=0.01。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Vascular risk factors are associated with cognitive decline but studies addressing individual risk factors have not demonstrated an effect of risk factor management on the preservation of cognition. Few trials have examined the effect of vascular risk factor management on function. OBJECTIVE: To determine if a polypill could reduce cognitive and functional decline in people with risk factors but without manifest cardiovascular disease. DESIGN, SETTING, AND PARTICIPANTS: The International Polycap Study 3 (TIPS-3) was a 2 × 2 × 2 factorial randomized clinical trial. Hospital and community-based centers in 8 countries recruited and followed up participants between July 30, 2012, and September 30, 2020. A total of 5713 individuals were randomly assigned to treatment groups, and 2098 people 65 years or older at intermediate risk of cardiovascular disease completed a cognitive assessment and were included in the analyses. INTERVENTIONS: Polypill (antihypertensives and a statin), aspirin, or a combination of both treatments. MAIN OUTCOMES AND MEASURES: Cognitive and functional assessments completed at baseline, 2 years, and study end. The primary outcome was the effect of a polypill compared with placebo and a polypill plus aspirin compared with double placebo on the composite outcome of the proportion of participants in each group who experienced a substantive decrease (>1.5 SD change) in cognitive or functional abilities. RESULTS: Of the 2389 study participants older than 65 years, a total of 2098 (88%; mean [SD] age, 70.1 [4.5] years; 1266 female individuals [60%]) completed the baseline and follow-up assessment. A total of 1796 participants (86%) had hypertension, and 680 participants (32%) had impaired fasting plasma glucose levels. Mean (SD) baseline systolic blood pressure was 146.1 (17.7) mm Hg, and mean (SD) low-density lipoprotein cholesterol (LDL-C) level was 124.3 (40.7) mg/dL and decreased by 5.7 mm Hg and 24 mg/dL, respectively, among those assigned to the polypill group. During a 5-year follow-up, there were no significant differences between treatment groups in the number of participants who experienced substantive cognitive decline (356 assigned polypill, 328 assigned placebo) or dementia (2 assigned polypill, 4 assigned placebo). Functional decline was reduced during follow-up for those assigned to polypill compared with placebo (mean [SD] country-standardized adjusted follow-up Standard Assessment of Global Everyday Activities [SAGEA] scores, 0.06 [0.03] vs 0.15 [0.03]; P = .01) and polypill plus aspirin compared with double placebo (mean [SD] country-standardized adjusted follow-up SAGEA scores, 0.01 [0.04] vs 0.14 [0.04]; P = .01). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of patients 65 years or older with vascular risk factors, a polypill, with or without aspirin, was not associated with reduced cognitive outcomes but was associated with reduced functional decline.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Bosch JJ, O'Donnell MJ, Gao P, et al. Effects of a Polypill, Aspirin, and the Combination of Both on Cognitive and Functional Outcomes: A Randomized Clinical Trial. JAMA Neurol. 2023. PMID: 36716007. doi:10.1001/jamaneurol.2022.5088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。